190 related articles for article (PubMed ID: 28945163)
1. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?
Hopson S; Casebeer A; Stemkowski S; Antol DD; Tao Z; Howe A; Patton J; Small A; Masaquel A
J Med Econ; 2018 Feb; 21(2):152-162. PubMed ID: 28945163
[TBL] [Abstract][Full Text] [Related]
2. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
3. Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
Pettersson K; Carlsson G; Holmberg C; Sporrong SK
Acta Oncol; 2012 Sep; 51(7):840-8. PubMed ID: 22937953
[TBL] [Abstract][Full Text] [Related]
4. Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings.
Fisher MD; Punekar R; Yim YM; Small A; Singer JR; Schukman J; McAneny BL; Luthra R; Malin J
J Oncol Pract; 2017 Jan; 13(1):e37-e46. PubMed ID: 27845870
[TBL] [Abstract][Full Text] [Related]
5. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Chimeric Antigen Receptor T-Cell Therapy by Site of Care Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Lyman GH; Nguyen A; Snyder S; Gitlin M; Chung KC
JAMA Netw Open; 2020 Apr; 3(4):e202072. PubMed ID: 32250433
[TBL] [Abstract][Full Text] [Related]
7. Cost of Disease Progression in Patients with Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, and Non-Hodgkin's Lymphoma.
Reyes C; Engel-Nitz NM; DaCosta Byfield S; Ravelo A; Ogale S; Bancroft T; Anderson A; Chen M; Matasar M
Oncologist; 2019 Sep; 24(9):1219-1228. PubMed ID: 30808814
[TBL] [Abstract][Full Text] [Related]
8. The Relationship Between Guideline-Recommended Initiation of Therapy, Outcomes, and Cost for Patients with Metastatic Non-Small Cell Lung Cancer.
Casebeer A; Antol DD; DeClue RW; Hopson S; Li Y; Khoury R; Michael T; Sehman M; Parikh A; Stemkowski S; Bunce M
J Manag Care Spec Pharm; 2018 Jun; 24(6):554-564. PubMed ID: 29799325
[TBL] [Abstract][Full Text] [Related]
9. Impact of transitioning inpatient chemotherapy regimens to the outpatient setting.
Corsi MP; Shea K; W Knoebel R
J Oncol Pharm Pract; 2020 Sep; 26(6):1324-1330. PubMed ID: 31822200
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
[TBL] [Abstract][Full Text] [Related]
11. Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple-negative breast cancer.
Aly A; Shah R; Hill K; Botteman MF
Future Oncol; 2019 Mar; 15(9):1007-1020. PubMed ID: 30717602
[TBL] [Abstract][Full Text] [Related]
12. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
13. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
14. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns for patients with advanced/metastatic cancers by site of care.
Bunniran S; Xu Y; Molife C; Nair R; Zhu YE; Carter GC; Sheth S; Hess LM
Am J Manag Care; 2021 Apr; 27(4):e105-e113. PubMed ID: 33877777
[TBL] [Abstract][Full Text] [Related]
16. Service setting impact on costs for bevacizumab-treated oncology patients.
Engel-Nitz NM; Yu EB; Becker LK; Small A
Am J Manag Care; 2014 Nov; 20(11):e515-22. PubMed ID: 25730350
[TBL] [Abstract][Full Text] [Related]
17. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
18. Implementation of a pharmacy-managed program for the transition of chemotherapy to the outpatient setting.
McBride A; Campen CJ; Camamo J; Maloney M; Persky D; Kurtin SE; Barket NL; Krishnadasan R; Elquza E; Anwer F; Weibel K
Am J Health Syst Pharm; 2018 May; 75(9):e246-e258. PubMed ID: 29691269
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Cost Comparison Evaluation of Inpatient Versus Outpatient Administration of EPOCH-Containing Regimens in Non-Hodgkin Lymphoma.
Evans SS; Gandhi AS; Clemmons AB; DeRemer DL
J Pharm Pract; 2017 Aug; 30(4):400-405. PubMed ID: 27432462
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
